A retrospective observational study to evaluate patient-reported outcomes (PROs) in patients with metastatic ALK plus non-small cell lung cancer (NSCLC) treated with ALK inhibitors

被引：0
|
作者：
Biber, Josh [1 ]
Wan, Yin [1 ]
Churchill, Eric N. [2 ]
Danes, Christopher G. [2 ]
Socinski, Mark A. [3 ]
Spira, Alexander I. [4 ]
机构：
[1] Takeda Dev Ctr Amer Inc, Lexington, MA USA
[2] Takeda Pharmaceut S Inc, Lexington, MA USA
[3] Advent Hlth Canc Inst, Orlando, FL USA
[4] Virginia Canc Specialists, Fairfax, VA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PP01.80
引用
收藏
页码：E36 / E36
页数：1
相关论文
共 50 条
  • [21] Qualitative research to evaluate perceptions around biomarker testing and patient-reported outcomes (PROs) for use in studies of non-small cell lung cancer (NSCLC)
    Horn, M. K.
    Mathias, S. D.
    Colwell, H.
    Heerdegen, A. C.
    Bevans, K.
    Li, T.
    Stevens, A.
    Sermon, J.
    Fastenau, J.
    Pierson, R.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S82 - S82
  • [22] Monitoring of ALK Fusions and Mutations in Advanced ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
    Mezquita, L.
    Remon, J.
    Nicotra, C.
    Noerholm, M.
    Brinkmann, K.
    Planchard, D.
    Jovelet, C.
    Auclin, E.
    Flinspach, C.
    Hurley, J.
    Skog, J.
    Gazzah, A.
    Caramella, C.
    Adam, J.
    Lacroix, L.
    Auger, N.
    Friboulet, L.
    Soria, J.
    Besse, B.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1954 - S1955
  • [23] CheckMate 078: Patient-Reported Outcomes (PROs) With Nivolumab vs Docetaxel in Advanced Non-Small Cell Lung Cancer (NSCLC)
    Wu, Y.
    Chang, J.
    Zhang, L.
    Tu, H.
    Wu, L.
    Feng, J.
    Lu, S.
    Zhou, C.
    Wang, J.
    Mok, T.
    Taylor, F.
    Mossman, B.
    Penrod, J.
    Lawrance, R.
    Blum, S.
    Wang, P. F.
    Cheng, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1047 - S1048
  • [24] Brain metastases and mortality in patients with ALK plus metastatic non-small cell lung cancer treated with second-generation ALK tyrosine kinase inhibitors as first-line targeted therapies: An observational cohort study
    Uprety, Dipesh
    Abrahami, Devin
    Marcum, Zachary A.
    Li, Benjamin
    Sang, Angela
    Davis, Matthew
    Rifi, Nada
    Kelton, John M.
    Ramaswamy, Krishnan
    Sanghvi, Parag
    Bazhenova, Lyudmila
    LUNG CANCER, 2025, 201
  • [25] Patient-reported outcomes and quality of life in advanced ALK plus non-small-cell lung cancer trial of brigatinib (ALTA)
    Lenderking, William R.
    Lin, Huamao
    Speck, Rebecca M.
    Zhu, Yanyan
    Huang, Hui
    Huang, Joice
    Kerstein, David
    Langer, Corey J.
    FUTURE ONCOLOGY, 2019, 15 (24) : 2841 - 2855
  • [26] Update of the INSPIRE study: Iruplinalkib versus crizotinib in ALK TKI-naive locally advanced or metastatic ALK plus non-small cell lung cancer (NSCLC)
    Shi, Y-K.
    Chen, J.
    Yang, R.
    Wu, H.
    Wang, Z.
    Yang, W.
    Cui, J.
    Zhang, Y.
    Liu, C.
    Cheng, Y.
    Liu, Y.
    Shan, J.
    Wang, D.
    Yang, L.
    Hu, C.
    Si, M.
    Li, H.
    Li, L.
    Kang, X.
    Wang, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S815 - S815
  • [27] ECONOMIC BURDEN OF PATIENTS WITH ALK plus MUTATION NON-SMALL CELL LUNG CANCER AFTER TREATMENT WITH CRIZOTINIB: A CANADIAN RETROSPECTIVE OBSERVATIONAL STUDY
    Kayaniyil, S.
    Wilson, J.
    Hurry, M.
    Koch, C.
    Zhang, J.
    Liu, G.
    VALUE IN HEALTH, 2015, 18 (07) : A452 - A452
  • [28] Real-world treatment outcomes with brigatinib in patients with pretreated ALK plus metastatic non-small cell lung cancer
    Popat, Sanjay
    Brustugun, Odd Terje
    Cadranel, Jacques
    Felip, Enriqueta
    Garassino, Marina Chiara
    Griesinger, Frank
    Helland, Aslaug
    Hochmair, Maximilian
    Perol, Maurice
    Bent-Ennakhil, Nawal
    Kruhl, Christian
    Novello, Silvia
    LUNG CANCER, 2021, 157 : 9 - 16
  • [29] Patient-Reported Outcomes (PROs) in Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC): PERLA Trial Comparing First-Line Chemotherapy Plus Dostarlimab or Pembrolizumab
    Reck, Martin
    Granados, Ana Laura Ortega
    de Marinis, Filippo
    Meyers, Oren
    Shen, Qin
    Cho, Lillian
    Boklage, Susan
    Gouldin, Winston
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E26 - E27
  • [30] Treatment Patterns and Survival among ALK plus Non-Small Cell Lung Cancer (NSCLC) Patients: A Chart Review Study
    Park, K.
    Cadranel, J.
    Arrieta, O.
    Pless, M.
    Bendaly, E.
    Patel, D.
    Sasane, M.
    Nosal, A.
    Guerin, A.
    Kageleiry, A.
    Stein, K.
    Marinsek, N.
    Zhang, J.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S638 - S638
12345